The expanding family of SMARCB1(INI1)-deficient Neoplasia: Implications of phenotypic, biological, and molecular heterogeneity

Advances in Anatomic Pathology

Volumn 21, Issue 6, 2014, Pages 394-410

  Agaimy, Abbas ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Gastrointestinal; INI1; Rhabdoid carcinoma; Rhabdoid tumor; Sarcoma; Sinonasal; SMARCB1

Indexed keywords

DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR; TUMOR MARKER;

BIOPSY; DEFICIENCY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOPLASM; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS;

BIOPSY; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84914102658     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000038     Document Type: Review

References (147)

1. Peterson CL, Dingwall A, Scott MP. Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement. Proc Natl Acad Sci USA. 1994;91:2905-2908
2. Dingwall AK, Beek SJ, McCallum CM, et al. The Drosophila snr1 and brm proteins are related to yeast SWI/SNF proteins and are components of a large protein complex. Mol Biol Cell. 1995;6:777-791
3. Neely KE, Hassan AH, Brown CE, et al. Transcription activator interactions with multiple SWI/SNF subunits. Mol Cell Biol. 2002;22:1615-1625
4. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28:1653-1668
5. Yaniv M. Chromatin remodeling: from transcription to cancer. Cancer Genet. 2014;pii:S2210-7762(14)00061-1
6. Roberts CW, Galusha SA, McMenamin ME, et al. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA. 2000;97:13796-13800
7. Klochendler-Yeivin A, Yaniv M. Chromatin modifiers and tumor suppression. Biochim Biophys Acta. 2001;1551:M1-10
8. Oike T, Ogiwara H, Nakano T, et al. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer. Jpn J Clin Oncol. 2013;43:849-855
9. Wang X, Haswell JR, Roberts CW. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer-mechanisms and potential therapeutic insights. Clin Cancer Res. 2014;20:21-27
10. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11:481-492
11. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8:e55119
12. Zhang ZK, Davies KP, Allen J, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol. 2002;22:5975-5988
13. Betz BL, Strobeck MW, Reisman DN, et al. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 2002;21:5193-5203
14. DelBove J, Kuwahara Y, Mora-Blanco EL, et al. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice. Mol Carcinog. 2009;48:1139-1148
15. Kuwahara Y, Charboneau A, Knudsen ES, et al. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. Cancer Res. 2010;70:1854-1865
16. Xu Y, Yan W, Chen X. SNF5, a core component of the SWI/ SNF complex, is necessary for p53 expression and cell survival, in part through eIF4E. Oncogene. 2010;29: 4090-4100
17. Judkins AR. Immunohistochemistry of INI1 expression: A new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol. 2007;14:335-339
18. Biegel JA, Rorke LB, Packer RJ, et al. Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg. 1990;73:710-714
19. Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206
20. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-79
21. Sévenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet. 1999;65:1342-1348
22. Biegel JA, Fogelgren B, Wainwright LM, et al. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosomes Cancer. 2000;28:31-37
23. Rousseau-Merck MF, Versteege I, Legrand I, et al. hSNF5/ INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res. 1999;59:3152-3156
24. Savla J, Chen TT, Schneider NR, et al. Mutations of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors. J Natl Cancer Inst. 2000;92:648-650
25. Taylor MD, Gokgoz N, Andrulis IL, et al. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet. 2000;66:1403-1406
26. Biegel JA, Kalpana G, Knudsen ES, et al. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 2002;62: 323-328
27. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/ INI1 gene in central nervous system atypical teratoid/ rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res. 2002;8:3461-3467
28. Janson K, Nedzi LA, David O, et al. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer. 2006;47:279-284
29. Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer. 2011;56:7-15
30. Hulsebos TJ, Plomp AS, Wolterman RA, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007;80:805-810
31. Rizzo D, Fréneaux P, Brisse H, et al. SMARCB1 deficiency in tumors from the peripheral nervous system: A link between schwannomas and rhabdoid tumors? Am J Surg Pathol. 2012;36:964-972
32. Hulsebos TJ, Kenter S, Verhagen WI, et al. Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathol. 2014;128:439-448
33. Kuge A, Sato S, Sakurada K, et al. Atypical teratoid rhabdoid tumor located in the pineal region following prophylactic irradiation for acute lymphoblastic leukemia. Brain Tumor Pathol. 2012;29:177-181
34. Wick MR, Ritter JH, Dehner LP. Malignant rhabdoid tumors: A clinicopathologic review and conceptual discussion. Semin Diagn Pathol. 1995;12:233-248
35. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer. 1978;41:1937-1948
36. Weeks DA, Beckwith JB, Mierau GW, et al. Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol. 1989; 13:439-458
37. Parham DM, Weeks DA, Beckwith JB. The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. Am J Surg Pathol. 1994;18:1010-1029
38. Fanburg-Smith JC, Hengge M, Hengge UR, et al. Extrarenal rhabdoid tumors of soft tissue: A clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol. 1998;2:351-362
39. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005;64:391-397
40. Hoot AC, Russo P, Judkins AR, et al. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004;28:1485-1491
41. Sigauke E, Rakheja D, Maddox DL, et al. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: An immunohistochemical study with implications for diagnosis. Mod Pathol. 2006;19:717-725
42. Bittesini L, Dei Tos AP, Fletcher CD. Metastatic malignant melanoma showing a rhabdoid phenotype: further evidence of a non-specific histological pattern. Histopathology. 1992;20: 167-170
43. Ogino S, Ro TY, Redline RW. Malignant rhabdoid tumor: A phenotype? An entity?-A controversy revisited. Adv Anat Pathol. 2000;7:181-190
44. Fuller CE, Pfeifer J, Humphrey P, et al. Chromosome 22q dosage in composite extrarenal rhabdoid tumors: clonal evolution or a phenotypic mimic? Hum Pathol. 2001;32: 1102-1108
45. Perry A, Fuller CE, Judkins AR, et al. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol. 2005;18:951-958
46. Bak M, Teglbjaerg PS. Pleomorphic (giant cell) carcinoma of the intestine. An immunohistochemical and electron microscopic study. Cancer. 1989;64:2557-2564
47. Agaimy A, Rau TT, Hartmann A, et al. SMARCB1 (INI1)- negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol. 2014;38: 910-920
48. Wu X, Dagar V, Algar E, et al. Rhabdoid tumour: A malignancy of early childhood with variable primary site, histology and clinical behaviour. Pathology. 2008;40:664-670
49. Kordes U, Gesk S, Frü hwald MC, et al. Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer. 2010;49:176-181
50. Bruggers CS, Bleyl SB, Pysher T, et al. Clinicopathologic comparison of familial versus sporadic atypical teratoid/ rhabdoid tumors (AT/RT) of the central nervous system. Pediatr Blood Cancer. 2011;56:1026-1031
51. Hasselblatt M, Oyen F, Gesk S, et al. Cribriform neuroepithelial tumor (CRINET): A nonrhabdoid ventricular tumor with INI1 loss and relatively favorable prognosis. J Neuropathol Exp Neurol. 2009;68:1249-1255
52. Park JY, Kim E, Kim DW, et al. Cribriform neuroepithelial tumor in the third ventricle: A case report and literature review. Neuropathology. 2012;32:570-576
53. Schneppenheim R, Frü hwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/ BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010;86:279-284
54. Hasselblatt M, Gesk S, Oyen F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/ rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 2011;35:933-935
55. Woehrer A, Slavc I, Waldhoer T, et al. Incidence of atypical teratoid/rhabdoid tumors in children: A population-based study by the Austrian Brain Tumor Registry, 1996-2006. Cancer. 2010;116:5725-5732
56. Kraus JA, Oster C, Sö rensen N, et al. Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene. Neuropathol Appl Neurobiol. 2002;28:136-141
57. Haberler C, Laggner U, Slavc I, et al. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol. 2006;30:1462-1468
58. Schittenhelm J, Nagel C, Meyermann R, et al. Atypical teratoid/rhabdoid tumors may show morphological and immunohistochemical features seen in choroid plexus tumors. Neuropathology. 2011;31:461-467
59. Sawamura Y, Nagashima K, Tanaka S. Case of atypical teratoid/rhabdoid tumor in an adult, with long survival. Brain Tumor Pathol. 2011;28:71-76
60. Raisanen J, Biegel JA, Hatanpaa KJ. Chromosome 22q deletions in atypical teratoid/rhabdoid tumors in adults. Brain Pathol. 2005;15:23-28
61. Ammerlaan AC, Ararou A, Houben MP, et al. Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. Br J Cancer. 2008;98:474-479
62. Kordes U, Bartelheim K, Modena P, et al. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatr Blood Cancer. 2014;61:919-921
63. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19:1-11
64. Amin MB, Smith SC, Agaimy A, et al. Collecting duct carcinoma versus renal medullary carcinoma: An appeal for nosologic and biological clarity. Am J Surg Pathol. 2014;38: 871-874
65. Guillou L, Wadden C, Coindre JM, et al. "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol. 1997;21:130-146
66. Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: A clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009;131:222-227
67. Enzinger FM. Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970;26:1029-1041
68. Fisher C. Epithelioid sarcoma of Enzinger. Adv Anat Pathol. 2006;13:114-121
69. Kosemehmetoglu K, Kaygusuz G, Bahrami A, et al. Intraarticular epithelioid sarcoma showing mixed classic and proximal-type features: report of 2 cases, with immunohistochemical and molecular cytogenetic INI-1 study. Am J Surg Pathol. 2011;35:891-897
70. Miettinen M, Wang Z, Sarlomo-Rikala M, et al. ERG expression in epithelioid sarcoma: A diagnostic pitfall. Am J Surg Pathol. 2013;37:1580-1585
71. Stockman DL, Hornick JL, Deavers MT, et al. ERG and FLI1 protein expression in epithelioid sarcoma. Mod Pathol. 2014;27:496-501
72. Machado I, Mayordomo-Aranda E, Scotlandi K, et al. Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection. Pathol Res Pract. 2014;210:508-513
73. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33:542-550
74. Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/ INI1 gene alteration in epithelioid sarcoma: A useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol. 2009;40:349-355
75. Sullivan LM, Folpe AL, Pawel BR, et al. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol. 2013;26:385-392
76. Le Loarer F, Zhang L, Fletcher CD, et al. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer. 2014;53:475-486
77. Brand A, Covert A. Malignant rhabdoid tumor of the vulva: case report and review of the literature with emphasis on clinical management and outcome. Gynecol Oncol. 2001;80:99-103
78. Plotkin SR, Blakeley JO, Evans DG, et al. Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet A. 2013;161A: 405-416
79. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011; 35:e47-e63, d
80. Carter JM, O'Hara C, Dundas G, et al. Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation. Am J Surg Pathol. 2012;36:154-160
81. Kohashi K, Oda Y, Yamamoto H, et al. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol. 2010;23:981-990
82. Mularz K, Harazin-Lechowska A, Ambicka A, et al. Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma. Pol J Pathol. 2012; 63:179-183
83. Arnold MA, Arnold CA, Li G, et al. A unique pattern of INI1 immunohistochemistry distinguishes synovial sarcoma from its histologic mimics. Hum Pathol. 2013;44:881-887
84. Rekhi B, Jambhekar NA. Immunohistochemical validation of INI1/SMARCB1 in a spectrum of musculoskeletal tumors: An experience at a Tertiary Cancer Referral Centre. Pathol Res Pract. 2013;209:758-766
85. Kadoch C, Crabtree GR. Reversible disruption of mSWI/ SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153:71-85
86. Kohashi K, Oda Y, Yamamoto H, et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: A special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 2008;32:1168-1174
87. Mobley BC, McKenney JK, Bangs CD, et al. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol. 2010;120:745-753
88. Tirabosco R, Jacques T, Berisha F, et al. Assessment of integrase interactor 1 (INI-1) expression in primary tumours of bone. Histopathology. 2012;61:1245-1247
89. Forest F, David A, Arrufat S, et al. Conventional chondrosarcoma in a survivor of rhabdoid tumor: enlarging the spectrum of tumors associated with SMARCB1 germline mutations. Am J Surg Pathol. 2012;36:1892-1896
90. Woo J, Seethala RR, Joseph Sirintrapun S. Mammary analogue secretory carcinoma of the parotid gland as a secondary malignancy in a childhood survivor of atypical teratoid rhabdoid tumor. Head Neck Pathol. 2014;8:194-197
91. Hulsebos TJ, Kenter S, Siebers-Renelt U, et al. SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis. Am J Surg Pathol. 2014;38:421-425
92. Graham RP, Dry S, Li X, et al. Ossifying fibromyxoid tumor of soft parts: A clinicopathologic, proteomic, and genomic study. Am J Surg Pathol. 2011;35:1615-1625
93. Yamamoto H, Kohashi K, Tsuneyoshi M, et al. Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor. Pathobiology. 2011;78: 132-139
94. Schaefer IM, Strö bel P, Cameron S, et al. Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply an aggressive behaviour. Histopathology. 2014;64: 421-430
95. Hanson JA, Trent JC, Yang D, et al. Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant. Int J Surg Pathol. 2011;19:653-657
96. Sommers SC, Meissner WA. Unusual carcinomas of the pancreas. Arch Path. 1954;58:101-111
97. Maggiani F, Debiec-Rychter M, Ectors N, et al. Primary epithelioid sarcoma of the oesophagus. Virchows Arch. 2007;451:835-838
98. Agaimy A, Haller F, Frohnauer J, et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. Mod Pathol. 2014, doi: 10.1038/modpathol.2014.100. [Epub ahead of print]
99. Pancione M, Remo A, Sabatino L, et al. Right-sided rhabdoid colorectal tumors might be related to the serrated pathway. Diagn Pathol. 2013;8:31
100. Keelawat S, Shuangshoti S, Kittikowit W, et al. Epithelioid sarcoma of the parotid gland of a child. Pediatr Dev Pathol. 2009;12:301-306
101. Frank R, Sadri N, Bhatti T, et al. Proximal-type epithelioid sarcoma of the head and neck (HN): A study with immunohistochemical and molecular analysis of SMARCB1. J Clin Exp Oncol. 2013;2:pii: 1000106
102. Jamshidi F, Pleasance E, Li Y. Diagnostic value of nextgeneration sequencing in an unusual sphenoid tumor. Oncologist. 2014;19:623-630
103. Agaimy A, Koch M, Lell M, et al. SMARCB1/INI1-deficient sinonasal basaloid carcinoma: A novel member of the expanding family of SMARCB1 deficient neoplasms. Am J Surg Pathol. 2014;38:1274-1281
104. Wieneke JA, Thompson LD, Wenig BM. Basaloid squamous cell carcinoma of the sinonasal tract. Cancer. 1999;85: 841-854
105. Sato K, Waseda R, Tatsuzawa Y, et al. Papillary thyroid carcinoma with anaplastic transformation showing a rhabdoid phenotype solely in the cervical lymph node metastasis. Pathol Res Pract. 2006;202:55-59
106. Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61:428-435
107. Elwood H, Chaux A, Schultz L, et al. Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma. Urology. 2011;78:474.e1-474.e5
108. Savage N1, Linn D, McDonough C, et al. Molecularly confirmed primary malignant rhabdoid tumor of the urinary bladder: implications of accurate diagnosis. Ann Diagn Pathol. 2012;16:504-507
109. Parwani AV, Herawi M, Volmar K, et al. Urothelial carcinoma with rhabdoid features: report of 6 cases. Hum Pathol. 2006;37:168-172
110. Perez-Montiel D, Wakely PE, Hes O, et al. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol. 2006;19:494-503
111. Gaertner EM, Farley JH, Taylor RR, et al. Collision of uterine rhabdoid tumor and endometrioid adenocarcinoma: A case report and review of the literature. Int J Gynecol Pathol. 1999;18:396-401
112. Al-Hussaini M, Hirschowitz L, McCluggage WG. Uterine neoplasms composed of rhabdoid cells do not exhibit loss of INI1 immunoreactivity and are not related to childhood malignant rhabdoid tumor. Int J Gynecol Pathol. 2008;27:236-242
113. Donner LR, Wainwright LM, Zhang F, et al. Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium. Hum Pathol. 2007;38:935-939
114. Venizelos I, Anagnostou E, Papathomas TG, et al. Proximaltype epithelioid sarcoma of the uterine corpus. Histopathology. 2011;58:321-323
115. Dickersin GR, Kline IW, Scully RE. Small cell carcinoma of the ovary with hypercalcemia: A report of eleven cases. Cancer. 1982;49:188-197
116. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18:1102-1116
117. Lamovec J, Bracko M, Cerar O. Familial occurrence of smallcell carcinoma of the ovary. Arch Pathol Lab Med. 1995;119:523-527
118. Kupryjań czyk J, Dansonka-Mieszkowska A, Moes-Sosnowska J, et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. a pilot study. Pol J Pathol. 2013;64: 238-246
119. Jelinic P, Mueller JJ, Olvera N, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014;46:424-426
120. Ramos P, Karnezis AN, Craig DW, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014;46:427-429
121. Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46:438-443
122. Tsai CY, Wong TT, Lee YH, et al. Intact INI1 gene region with paradoxical loss of protein expression in AT/RT: implications for a possible novel mechanism associated with absence of INI1 protein immunoreactivity. Am J Surg Pathol. 2012;36:128-133
123. Haberler C. Intact INI1 gene region with paradoxical loss of protein expression in AT/RT: implications for a possible novel mechanism associated with absence of INI1 protein immunoreactivity. Am J Surg Pathol. 2012;36:1903-1904
124. Zhang F, Tan L, Wainwright LM, et al. No evidence for hypermethylation of the hSNF5/INI1 promoter in pediatric rhabdoid tumors. Genes Chromosomes Cancer. 2002;34: 398-405
125. Albanese P, Belin MF, Delattre O. The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. Eur J Cancer. 2006;42:2326-2334
126. Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122:2983-2988
127. Kieran MW, Roberts CW, Chi SN, et al. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer. 2012;59: 1155-1157
128. Hasselblatt M, Isken S, Linge A, et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer. 2013;52:185-190
129. Takita J, Chen Y, Kato M, et al. Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays. Cancer Sci. 2014;105:258-264
130. Cajuso T, Hä nninen UA, Kondelin J, et al. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int J Cancer. 2014;135:611-623
131. Chou A, Toon CW, Clarkson A, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014;45:1697-1703
132. Cho YM, Choi J, Lee OJ, et al. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features. Pathol Int. 2006;56:702-706
133. Kleinschmidt-DeMasters BK, Birks DK, Aisner DL, et al. Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterization. Am J Surg Pathol. 2011;35:1894-1901
134. Hertwig F, Meyer K, Braun S, et al. Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells. Cancer Res. 2012;72:3381-3392
135. Bourdeaut F, Fréneaux P, Thuille B, et al. hSNF5/INI1- deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol. 2007;211:323-330
136. Birks DK, Donson AM, Patel PR, et al. Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes. Pediatr Blood Cancer. 2013;60:1095-1102
137. Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21:647-652
138. Foulkes WD, Clarke BA, Hasselblatt M, et al. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. J Pathol. 2014; 233:209-214
139. Kerl K, Holsten T, Frü hwald MC. Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy. Pediatr Hematol Oncol. 2013;30:587-604
140. Gadd S, Sredni ST, Huang CC, et al. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest. 2010;90:724-738
141. Jagani Z, Mora-Blanco EL, Sansam CG, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010;16:1429-1433
142. Smith ME, Cimica V, Chinni S, et al. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1. Proc Natl Acad Sci USA. 2011;108:319-324
143. Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro-oncol. 2013;15: 149-160
144. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110:7922-7927
145. Satomi K, Morishita Y, Murata Y, et al. Epidermal growth factor receptor abnormalities in atypical teratoid/rhabdoid tumors and an unusual case with gene amplification. Pathol Res Pract. 2013;209:521-526
146. Wö hrle S, Weiss A, Ito M, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 2013;8:e77652
147. Sredni ST, Bonaldo Mde F, Costa FF, et al. Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nerv Syst. 2010;26: 279-283.